Tamsulosin works better on large kidney stones

Tamsulosin works no better than placebo on small kidney stones, but does improve passage of more large kidney stones than placebo does. The results of this large clinical trial evaluating tamsulosin versus placebo were published online Friday in Annals of Emergency Medicine ("Distal Ureteric Stones and Tamsulosin: A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Trial (The DUST Trial)").

"Kidney stones bring more than a million Americans a year to emergency departments because they are excruciatingly painful," said lead study author Jeremy Furyk, MBBS, MPH and TM of The Townsville Hospital in Townsville, Queensland, Australia. "The news on small kidney stones isn't positive, but tamsulosin appears to offer benefit to those unlucky people whose kidney stones are really big."

Within 28 days of a visit to the emergency department, kidney stone passage occurred in 87 percent of patients treated with tamsulosin and 81.9 percent of those treated with placebo, a difference not considered significant. However, 83.3 percent of patients treated with tamsulosin whose kidney stones measured between 5 and 10 millimeters in length passed their stones, compared to only 61 percent of those who were treated with placebo.

"For patients with small kidney stones, time seems to be the one sure cure," said Dr. Furyk. "However, when treating patients with large kidney stones, emergency physicians should definitely consider tamsulosin."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research reveals how Hepatitis E virus can lead to kidney disease